|
|
Article: Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study.
- Article from:
- PR Newswire
- Article date:
- April 14, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA, showing good bioavailability and predictable serum levels of subcutaneously administered BiTE(R) antibodies(1). BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.
Micromet conducted a pharmacokinetic study in non-human primates exploring ...